SCHEMBL13340922

SCHEMBL13340922

CCn1c(=O)oc2cc(C(C)C)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
MIF P14174 2/20 0.43
RORC P51449 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
PDE10A Q9Y233 1/20 0.41
NPC1 O15118 1/20 0.40
HPGD P15428 2/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
RORA P35398 1/20 0.40
RORB Q92753 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13341148 0.88 MIF (0.50) SMN1; SMN2ALDH1A1TP53POLBMAPT
SCHEMBL13341138 0.84 POLB (0.44) SMN1; SMN2ALDH1A1TP53POLBMAPT
SCHEMBL13340920 0.81 HPGD (0.59) SMN1; SMN2TP53POLBMAPTMEN1
SCHEMBL13341017 0.81 PPARG (0.46) SMN1; SMN2TP53POLBMAPTMIF
SCHEMBL13340923 0.79 MEN1 (0.45) SMN1; SMN2TP53POLBMAPTMEN1
SCHEMBL13367743 0.79 MIF (0.66) SMN1; SMN2ALDH1A1POLBMIFMEN1
SCHEMBL10238652 0.79 MEN1 (0.61) ALDH1A1TP53POLBMAPTMEN1
SCHEMBL13341140 0.78 SIGMAR1 (0.61) POLBSIGMAR1
SCHEMBL14044191 0.78 LMNA (0.59) SMN1; SMN2ALDH1A1TP53POLBMAPT
SCHEMBL3036188 0.78 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1MAPTMIFRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS SMN1; SMN2 1213/4885ALDH1A1 1085/4885TP53 7/4885
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ SMN1; SMN2 2625/4885ALDH1A1 3843/4885TP53 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.